上海民为生物技术有限公司
SHANGHAI MINWEI BIOTECHNOLOGY CO.,LTD

English

English

中文

Events

2025

Recently, Shanghai Minwei Biotechnology Co., Ltd. signed a licensing agreement for MWN105 injection with Sidera Bio Aps. This cooperation marks an important milestone for Shanghai Minwei Biotechnology in its internationalization journey, indicating that the company's innovative capabilities have been recognized by global peers. Through this authorization, the clinical development and commercialization process of this innovative drug in the international market will be accelerated, which also confirms that the company's research and development in the field of endocrine and metabolic therapy has entered the global advanced ranks. The company will continue to increase investment in scientific research and innovation, improve the R&D system, and create more high-quality drugs.

MWN105 injection is a triple agonist of GLP-1/GIP/FGF21 receptors independently developed by Shanghai Minwei Biotechnology, a subsidiary of Lepu Medical. It holds global intellectual property rights and can synergistically promote insulin secretion, improve insulin sensitivity, and ameliorate the progression of liver steatosis, inflammation and fibrosis.

MWN105 Phase II, in September 2025, the first subject received the first dose of the drug.

Phase II of MWN109 injection, August 23, 2025, first dose administration to the first subject

MWX203 injection, phase 1, on July 8, 2025, the first subject received the first dose

2025-09

2025-08

2025-07

2025-6

On June 6, 2025, Minwei Bio initiated the Phase I clinical trial of its oral GLP-1/GIP/GCG. This is the world's first new drug that is an oral triple-target agonist of GLP-1/GIP/GCG.

2025-5

On May 27, 2025, IND approval was granted! The National Medical Products Administration officially approved Shanghai Minwei Biotechnology's MWX203 injection for clinical trials.

2025-3

IND for clinical trial of MWN109 tablets was submitted, and accepted by NMPA On March 4, 2025

2024-11

For Minwei's clinical trial MWN101, phase II study was successfully completed in Nov 2024.
For Minwei's clinical trial MWN105, approval of CDE was acquired in 20 Nov 2024.
For Minwei's clinical trial MWN109, approval of CDE was acquired in 24 Nov 2024.For Minwei's clinical trial MWN203, submission of preIND to CDE was done in Nov 2024.

2024-12

The MWN109 injection of Minwei Biology has obtained the clinical approval from the US FDA.

The MWN109 project for the treatment of NASH has obtained the clinical approval for the indication.

2024

2024-05

Minwei Bio has submitted Pre-IND applications for multiple indications for the MWN105 and MWN109 projects. It is expected that Phase 1 clinical trials will commence by the end of the year. Meanwhile, the global first multi-target oral peptide tablet, MWN109, is also nearing the submission of its Pre-IND application.

2024-03

Minwei Bio has moved its entire operation to Zhangjiang Gene Island and established a new nearly 3,000-square-meter new drug R&D laboratory.

Appearance of Minwei Biopharma

R&D Laboratory of Minwei Biopharma

2024-01

Minwei Biopharma's MWN101 project has successively launched Phase II multicenter clinical studies for two indications, competing head-to-head with semaglutide in the field of type 2 diabetes. Based on the excellent safety data from Phase I, Phase II has been approved to try higher doses of administration.

2023-12

The Phase I clinical study of Minwei Biopharma's MWN101 project for its two indications has successfully concluded, with excellent safety data and PK (pharmacokinetic) data achieved across six dose groups for both SAD (single ascending dose) and MAD (multiple ascending dose) studies.

2023

2023-06

Minwei Biopharma has secured nearly RMB 400 million in industrial investment from Lepu Medical.

2022-10

Shanghai Minwei Bio has submitted two pre-IND (pre-Investigational New Drug) applications for MWN101, one for the treatment of type 2 diabetes and the other for the treatment of overweight or obesity.

2022

2022-05

Shanghai Minwei Bio has obtained a patent authorization related to its MWN101 project.

2021-06

Shanghai Minwei Bio has successfully completed its first round of financing, raising nearly RMB 100 million.

2021

2021-05

Shanghai Minwei Bio has completed the full acquisition of Dongguan Yunjing Biotechnology Co., Ltd.

2021-04

Shanghai Minwei Bio has officially been established.

hr@minweibiotech.com

021-20961910